USING MOLECULAR MODELLING AND BIOLOGICAL EXPERIMENTATION TO CHARACTERIZE AN ALLOSTERIC NANOBODY
We describe the first single-domain antibody fully activating a GPCR selectively. This nanobody activates only Mglu4 subtype, an interesting target for the treatment of Parkinson’s disease or pain. Using modeling tools, we show this nanobody acts by stabilizing the active form of the binding domain.
• Learn about the latest advancements antibody characterization
• See the benefits in combining modeling and biological experimentation
• Understand allosteric nanobody behavior prediction
Anne Goupil-Lamy, Principal Scientist and BIOVIA Science council fellow
• Anne Goupil-Lamy, Ph.D., Science Council Fellow at BIOVIA, obtained her doctorate in Molecular Biophysics from the Sorbonne University, Paris. She has been in charge of BIOVIA' contract research group for many years and today she is involved in many scientific collaborations with industrial partners and academic teams.
Jean–Philippe Pin, CNRS research director
• Jean-Philippe Pin participated in the discovery of metabotropic glutamate receptors. Since then, he has been studying the allosteric modulation and activation mechanism of this family of G protein coupled receptors using innovative approaches, including biosensors, photoswitchable ligands and nanobodies as pharmacological tools and potential therapeutic agents.